Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV's positive outlook is largely driven by an increased global peak sales estimate for its oral bradykinin B2 receptor antagonist, deucrictibant, now projected to reach $1.65 billion by 2037, reflecting robust market potential. The drug has demonstrated significant patient benefits, with 100% of participants in clinical studies achieving "well-controlled HAE" status and reporting improvements in health-related quality of life, indicating its efficacy and durability as a treatment option. Additionally, the absence of approved therapies in a patient population with a prevalence of approximately 1:100,000 – 1:500,000 positions deucrictibant strongly to capture substantial market share if approved.

Pharvaris NV faces significant challenges in its development of deucrictibant for HAE treatment, primarily due to the inadequacy of de-risking bradykinin B2 receptor antagonism in chronic prophylaxis settings. The highly competitive landscape of the HAE market, characterized by established segment leaders and their dominant therapies, poses a threat to Pharvaris's market viability. Additionally, the anticipated approval of multiple subcutaneous therapies within the next 36 months raises concerns about potential market share erosion and reduced uptake of deucrictibant, contributing to a negative outlook on the stock.